Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) Director Suzanne Ildstad sold 15,713 shares of the firm’s stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $2.56, for a total value of $40,225.28. Following the completion of the transaction, the director now owns 2,805,682 shares in […]
Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) was the recipient of a large decrease in short interest in the month of April. As of April 30th, there was short interest totalling 784,300 shares, a decrease of 15.8% from the April 15th total of 931,200 shares. Based on an average daily volume of 397,400 shares, the […]
Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) Director Suzanne Ildstad sold 15,004 shares of the firm’s stock in a transaction that occurred on Friday, April 21st. The shares were sold at an average price of $2.35, for a total value of $35,259.40. Following the completion of the transaction, the director now directly owns 2,821,395 shares […]
Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) Director Suzanne Ildstad sold 99,771 shares of the stock in a transaction on Monday, April 17th. The shares were sold at an average price of $2.14, for a total value of $213,509.94. Following the completion of the sale, the director now owns 2,954,353 shares of the company’s stock, […]
HC Wainwright lowered shares of Talaris Therapeutics (NASDAQ:TALS – Get Rating) from a buy rating to a neutral rating in a report published on Monday morning, The Fly reports. Separately, Morgan Stanley reduced their price objective on Talaris Therapeutics from $6.00 to $3.00 and set an equal weight rating for the company in a report […]